BioWorld

Oct. 29, 2007

Kosan, Roche End Partnership; Epothilone Goes Back Home

Kosan Biosciences Inc. and Roche Holding AG ended their five-year collaboration to develop and commercialize epothilones, anticancer agents that inhibit cell division. (BioWorld Today) Read More

Biotech Allozyne Improving Protein Drugs With $30M Round

Jennerex Seeks Oncolytic Strait Between Scylla And Charybdis

Clinical Data IVD Asset Sale: $19.5M For Drug, Test Bids

NovaBay Prices IPO At $4/Share Gets $20M To Advance Pipeline

Other News To Note

Clinic Roundup

Earnings Roundup

AACR Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...

Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent

BioWorld Science

Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...